Threading prior knowledge into new material makes for more durable learning. Here are 12 research-backed, teacher-tested strategies to help kids unpack what they already know.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 13 High-Risk High-Reward Growth Stocks to Invest In. Guggenheim, on February 10, raised its target price on Praxis Precision (PRAX) by 5.3% ...

Jim Garrison, a social and political activist and author, will be featured in a Praxis Peace Institute online event focusing ...

ETS's Praxis® program, the leading provider of teacher licensure assessments, today announced the launch of Futurenav Adapt AI for teachers, an assessment that generates AI readiness insights for K-12 ...

Praxis specializes in using genetic insights to discover new therapies for neurological disorders. The biotech's efforts received a boost today when the U.S. Food and Drug Administration (FDA) granted ...

Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...

Praxis Precision Medicines (PRAX) just hit a double inflection point, with its EMBOLD trial for relutrigine stopped early for efficacy and a successful pre-NDA meeting for ulixacaltamide setting up a ...

Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early ...

Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock surged 25% after the company announced its EMBOLD study evaluating relutrigine was stopped early due to positive efficacy results. The ...

Praxis Precision (PRAX) announced results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic ...